Journal
SWISS MEDICAL WEEKLY
Volume 140, Issue -, Pages 14-19Publisher
E M H SWISS MEDICAL PUBLISHERS LTD
DOI: 10.4414/smw.2010.13112
Keywords
Kras; metastatic colorectal cancer; anti-EGFR-therapy; predictive markers
Categories
Funding
- ELT-FP6 [LSHC-CT-2004-503224]
- EU [TuMIC 2008-201662]
- NCCR Molecular Oncology of the Swiss National Science Foundation
- Swiss Cancer League
- Krebsliga beider Basel
- Gebert-Ruf Foundation
- Desiree and Nils Yde Foundation
Ask authors/readers for more resources
Kras, a small intracellular GTPase, is a central intermediary of the epidermal growth factor receptor (EGFR) and other tyrosine kinase receptor pathways. Increased EGFR and Kras signalling is involved in colorectal carcinogenesis and tumour progression. Mutations of Kras result in the loss of its GTPase activity and thus in a constitutive activation of Kras signalling. Kras mutations are found in 30-60% of colorectal cancers. The concordance between Kras mutations in the primary tumour and related metastatic sites is high. Since mutation of Kras confers resistance to anti-EGFR-antibody therapy, it is critical to assess Kras mutational status in colorectal cancer patients. Anti-EGFR-antibody therapy improves survival in patients with metastatic colorectal cancer and wild-type Kras.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available